While the most notable clinical benefit has been observed in endometrial cancer patients (149), including a documented case of PIK3CA-mutated endometrial cancer achieving a clinically meaningful response (150), in ovarian cancer cohorts, patients with OCCC demonstrated a disease control rate of 50% (2 stable disease, 1 partial response) (149). The gene discussed is PIK3CA; the disease is ovarian carcinoma.